ERBB2 and breast cancer: The results are complemented by a multivariate analysis of mpIHC-based biomarkers for hypoxia and hypoxia-induced neoangiogenesis, in which luminal A breast cancers were clearly separated from Her2+ and triple-negative breast cancers.